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Introduction: The identification of early, preferably presymptomatic, biomarkers and true etiologic factors for
Alzheimer’s disease (AD) is the first step toward establishing effective primary and secondary prevention programs.
Consequently, the search for a relatively inexpensive and harmless biomarker for AD continues. Despite intensive
research worldwide, to date there is no definitive plasma or blood biomarker indicating high or low risk of
conversion to AD.
Methods: Magnetic resonance imaging and β-amyloid (Aβ) levels in three blood compartments (diluted in plasma,
undiluted in plasma and cell-bound) were measured in 96 subjects (33 with mild cognitive impairment, 14 with AD
and 49 healthy controls). Pearson correlations were completed between 113 regions of interest (ROIs) (45 subcortical
and 68 cortical) and Aβ levels. Pearson correlation analyses adjusted for the covariates age, sex, apolipoprotein E (ApoE),
education and creatinine levels showed neuroimaging ROIs were associated with Aβ levels. Two statistical methods
were applied to study the major relationships identified: (1) Pearson correlation with phenotype added as a covariate
and (2) a meta-analysis stratified by phenotype. Neuroimaging data and plasma Aβ measurements were taken from
630 Alzheimer’s Disease Neuroimaging Initiative (ADNI) subjects to be compared with our results.
Results: The left hippocampus was the brain region most correlated with Aβ(1–40) bound to blood cell pellets
(partial correlation (pcor) = −0.37, P = 0.0007) after adjustment for the covariates age, gender and education, ApoE
and creatinine levels. The correlation remained almost the same (pcor = −0.35, P = 0.002) if phenotype is also
added as a covariate. The association between both measurements was independent of cognitive status. The left
hemisphere entorhinal cortex also correlated with Aβ(1–40) cell-bound fraction. AB128 and ADNI plasma Aβ
measurements were not related to any brain morphometric measurement.
Conclusions: Association of cell-bound Aβ(1–40) in blood with left hippocampal volume was much stronger than
previously observed in Aβ plasma fractions. If confirmed, this observation will require careful interpretation and
must be taken into account for blood amyloid-based biomarker development.Introduction
Alzheimer’s disease (AD) is the most frequent cause of
dementia in Western societies. Neuropsychological
evaluation remains the most useful tool for the diagnosis
of AD and mild cognitive impairment (MCI) [1]. However,
new biomarkers, such as amyloid-β protein fragment
1–42 (Aβ42) and phospho-tau protein levels in cerebrospinal* Correspondence: osotolongo@fundacioace.com
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article, unless otherwise stated.fluid (CSF) measured by magnetic resonance imaging
(MRI)–based hippocampal volumetry, have also been pro-
posed [2]. More recently, direction of Aβ or tau using ra-
diotracers in positron emission tomography has emerged
as a promising candidate for improving diagnosis and
monitoring drug treatments and disease progression.
Although Aβ levels in plasma have been widely investi-
gated as a potential biomarker for AD evaluation, the de-
velopment of a blood-based test to diagnose AD has
remained elusive. Therefore, no definitive plasma or blood
biomarker that can be used to indicate high or low risk
of conversion to AD has been confirmed to date [3].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Study demographics of the AB128 study
subjectsa
HC MCI AD
Number of subjects 49 33 14
Age (yr) 56.2 (5.6) 74.6 (6.4) 79.5 (5.3)
Education (% >8 yr) 94 33 64
Gender (% males) 26.5 27.3 28.6
ApoE (% ε4 allele) 64.3 57.6 64.3
Creatinine (mg/dl) 0.77 (0.11) 0.83 (0.2) 0.89 (0.27)
DA Aβ(1–40) (pg/ml) 38.9 (10.5) 58.1 (16.3) 50.3 (18.7)
TP Aβ(1–40) (pg/ml) 83.3 (18.0) 93.0 (16.3) 93.8 (19.5)
CP Aβ(1–40) (pg/ml) 58.0 (10.3) 55.0 (14.1) 64.4 (10.7)
DA Aβ(1–42) (pg/ml) 13.5 (14.8) 12.1 (15.0) 12.4 (9.4)
TP Aβ(1–42) (pg/ml) 52.2 (33.5) 49.7 (40.9) 55.8 (30.4)
CP Aβ(1–42) (pg/ml) 164.6 (77.0) 154.6 (71.1) 163.3 (54.5)
aAD: Alzheimer’s disease; ApoE: Apolipoprotein E; Aβ: Amyloid-β; CP: Cellular
pellet; DA: Directly accessible; HC: Healthy control; MCI: Mild cognitive
impairment; RP: Recovered from plasma; TP: Total in plasma. Mean value is the
number reported and the standard deviation is in brackets, as applicable.
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the plasma, bound to plasma proteins and bound to blood
cells [4]. There are several enzyme-linked immunosorbent
assay (ELISA)–based tests to measure only free Aβ in
plasma [5-8]. In fact, most studies reported to date have
been related to the measurement of Aβ levels in plasma
fraction [9-11]. However, as the majority of Aβ peptides
are bound to blood cells [12], a comprehensive Aβ blood
test must include the determination of peptide levels in
each of these three fractions.
Our group is actively involved in the development of
novel sandwich ELISA colorimetric tests for detection
of Aβ using whole blood instead of plasma alone [4,13].
In fact, this technology was used in a recently conducted
trial, titled the AB128 project, in which we studied Aβ
blood level as a potential AD biomarker. Specifically, we
found statistically significant differences in some measure-
ments in different blood compartments when we data
from compared healthy controls (HCs) and subjects with
MCI [14].
In this work, we aim to establish a relationship between
blood Aβ levels obtained using these novel ELISA tech-
niques and brain morphometry measured using MRI in
healthy and cognitively impaired individuals. We postu-
lated that if the blood Aβ load is associated with AD, those
biomarker levels could be related to brain regions of inter-
est (ROIs) previously defined for AD. Therefore we under-
took a data exploration to identify blood Aβ measurement
methods which correlated with brain volume.
Methods
Study population
The study included 96 participants divided into three
clinical groups based on their cognitive status, compris-
ing 33 patients with amnesic MCI, 14 patients with AD
and 49 HCs. AD, HC and MCI criteria used to recruit
subjects in this study are described in our earlier work
[4,13]. Briefly, cognitive assessment was performed ac-
cording to routine procedures utilized at the Fundació
ACE Memory Clinic (Barcelona, Spain), as described
elsewhere [14]. MCI subjects fulfilled the Petersen’s diag-
nostic criteria [15], including subjective memory com-
plaints, normal general cognition, preserved performance
in activities of daily living, absence of dementia and a
measurable impairment in memory function, with or
without deficit in other cognitive domains [16]. All MCI
subjects had a Clinical Dementia Rating (CDR) of 0.5.
On the basis of the Cut-off scores of a Brief Neuro-
psychological Battery (NBACE, a subtest of the Wechs-
ler Memory Scale III) [14], impaired delayed verbal
recall for which recognition testing does not improve
performance classifies patients with amnesic MCI as
having an “encoding/storage” pattern of memory loss.
The diagnosis of AD was made according to NationalInstitute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related
Disorders Association [17,18] criteria, where AD is de-
fined as a CDR of 1 point or more and a Mini Mental
State Examination (MMSE) score below 24. HCs were
cognitively normal when evaluated at the Fundació ACE
Memory Clinic, had MMSE scores of at least 26 (taking
into consideration the MMSE cutoff of <25 in the Spanish
population [19]) and had a normal neuroimaging MRI
profile.
Subject demographic characteristics are listed in Table 1.
Written informed consent was obtained from each partici-
pant or, in several AD patients, the closest relative. The
study protocols were reviewed and approved by the ethics
committee of the Hospital Clinic i Provincial (Barcelona,
Spain).
Blood sampling and biochemical determinations
Blood samples from each participant were drawn on the
morning after an overnight fast and were collected in
polypropylene vials with ethylenediaminetetraacetic acid
and a protease inhibitor cocktail (Complete Mini; Roche,
Madrid, Spain). The samples were immediately cooled to
4°C until processing, which occurred within 24 hours
after collection. Blood samples were centrifuged, and
both the plasma and the cellular pellet (CP) were divided
into aliquots and stored in polypropylene tubes at −80°C
until analyzed. The material was not thawed or refrozen
at any time. All samples were analyzed in triplicate in
the same run for each of the three blood fractions using
two specific sandwich ELISA kits, ABtest 40 and ABtest
42 (Araclon Biotech, Zaragoza, Spain), as described else-
where [4]. Before analysis, plasma and blood cell samples
Table 2 Alzheimer’s Disease Neuroimaging Initiative
subject demographicsa
HC MCI AD
Number of subjects 185 307 138
Age (yr) 76.0 (5.1) 74.8 (7.4) 75.3 (7.5)
Education (yr) 16.2 (2.8) 15.8 (3.0) 14.6 (3.2)
Gender (% males) 53.0 63.2 50.7
ApoE (% ε4 allele) 26.5 53.1 65.9
Creatinine (g/L) 114.0 (73.5) 114.3 (69.5) 105.6 (62.6)
Aβ(1–40) (pg/ml) 151.4 (49.7) 152.0 (55.7) 152.2 (40.1)
Aβ(1–42) (pg/ml) 37.8 (12.2) 36.4 (11.8) 36.4 (10.0)
aAD: Alzheimer’s disease; ApoE: Apolipoprotein E; Aβ: Amyloid-β; HC: Healthy
control; MCI: Mild cognitive impairment. Mean value is the number reported
and the standard deviation is in brackets, as applicable.
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with 1% blocking polymer according to the supplier’s in-
structions. We carried out three counts for both the Aβ40
and Aβ42 peptides in each blood sample. One count was
performed using the undiluted plasma sample, another
using the plasma sample diluted 1:3 with the aforemen-
tioned formulated buffer and a third using the CP that
remained after plasma collection. The peptide amount in
the undiluted plasma sample corresponded to the directly
accessible (DA) peptide. The 1:3 dilution of the plasma
was chosen because it provided the maximum peptide re-
covery from the sample (that is, the total in plasma (TP)).
Thus, this count included the DA peptide and the peptide
that was recovered from the plasma matrix. Additionally,
the peptide associated with the CP was measured in a 1:5
dilution of the pellet that remained after plasma collection.
The sum of these three amounts is described as the total
Aβ pool in blood for either Aβ(1–40) or Aβ(1–42).
Brain imaging and magnetic resonance imaging analysis
All MRI scans were performed with a 1.5-T MRI scanner
(Magnetom Symphony; Siemens Medical Solutions,
Erlangen, Germany) at the Department of Diagnostic
Imaging, Corachan Clinic, Barcelona. The protocol for the
acquisition of the MRI data was identical for all patients
and consisted of three-dimensional T1-weighted sagittal
Magnetization-prepared rapid acquisition with gradient
echo, two-dimensional (2D) axial T2-weighted turbo spin
echo, 2D axial fluid-attenuated inversion recovery, 2D
axial T2*-weighted gradient echo and 2D axial diffusion-
weighted imaging. Brain images were also visually inspected
by experienced clinicians who were blinded to the partici-
pants’ demographic, anthropometric and clinical data.
Cortical reconstruction and volumetric segmentation
were performed with the Freesurfer image analysis suite,
which is documented and freely available for download
online. The technical details of these procedures are also
described in prior publications (see [20,21] and refer-
ences therein).
Briefly, this processing method includes motion correc-
tion and averaging of multiple volumetric T1-weighted im-
ages (when more than one image is available), removal of
nonbrain tissue performed by using a hybrid watershed/
surface deformation procedure, an automated Talairach
transformation, segmentation of the subcortical white
matter and deep gray matter volumetric structures (in-
cluding hippocampus, amygdala, caudate, putamen and
ventricles), intensity normalization, tessellation of the
gray-matter–white-matter boundary, automated top-
ology correction and surface deformation following in-
tensity gradients to optimally place the gray–white and
gray–cerebrospinal fluid borders at the location where
the greatest shift in intensity defines the transition to
the other tissue class.Once the cortical models are complete, a number of
deformable procedures can be performed for further
data processing and analysis, including surface inflation,
registration to a spherical atlas by utilizing individual cor-
tical folding patterns to match cortical geometry across
subjects, parcellation of the cerebral cortex into units
based on gyral and sulcal structures and creation of a var-
iety of surface based data including maps of curvature and
sulcal depth. With this method, both intensity and con-
tinuity information from the entire three-dimensional MR
volume in segmentation and deformation procedures to
produce representations of cortical thickness, which are
calculated as the closest distance from the gray-matter–
white-matter boundary to the gray-matter–CSF boundary
at each vertex on the tessellated surface. The maps are
created using spatial intensity gradients across tissue clas-
ses and are therefore not reliant on absolute signal inten-
sity only. The maps produced are not restricted to the
voxel resolution of the original data; thus, they are capable
of detecting submillimetric differences between groups. It
should be noted that the procedures described here for
the measurement of cortical thickness have been validated
against histological analysis [22] and manual measure-
ments [23,24]. Freesurfer morphometric procedures have
been proven to show good test–retest reliability across
scanner manufacturers and across field strengths [20,21].Alzheimer’s Disease Neuroimaging Initiative data
For later comparison of results obtained in the AB128
project, the ADNI repository was explored for subjects
with full data for MRI, Aβ plasma, age, gender and apo-
lipoprotein E (ApoE), education and creatinine levels.
Following these criteria, the data of 630 subjects were
downloaded from the ADNI repository [1]. The demo-
graphic characteristics of these subjects are shown in
Table 2. Other details of the ADNI cohort can be found
online.
Table 3 Hippocampal volume partial correlations with










Aβln DA Aβ(1–40) 0.05 0.64 −0.01 0.92
Aβln DA Aβ(1–42) −0.08 047 −0.15 0.20
Aβln TP Aβ(1–40) 0.03 0.78 0.01 0.92
Aβln TP Aβ(1–42) −0.01 0.37 −0.14 0.22
Aβln CP Aβ(1–40)* −0.37 0.0007 −0.35 0.002
Aβln CP Aβ(1–42) −0.16 0.17 −0.2 0.07
Total Aβ1 −0.18 0.11 −0.24 0.03
ADNI Aβln Aβ(1–40) 0.08 0.05 0.1 0.01
ADNI Aβln Aβ(1–42) 0.08 0.04 0.09 0.02
aADNI: Alzheimer’s Disease Neuroimaging Initiative; Aβ: Amyloid-β; CP: Cellular
pellet; DA: Directly accessible. The data are derived from the AB128 and ADNI
data sets and represent partial correlations of Aβ blood levels with left
hippocampal volume adjusted for the covariates age, gender, ApoE, education,
creatinine levels and phenotype. The left columns show the correlations and
P-values if phenotype is excluded as covariate. ADNI Aβln Aβ(1–40) and Aβln
Aβ(1–42) values are placed underneath their comparative quantities. *Bold text
highlights the correlation of the Aβln CP Aβ(1–40) fraction in the AB128 study.
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levels of the ADNI project subjects were measured using
module A of the INNO-BIA plasma Aβ forms immuno-
assay kit (Innogenetics, Ghent, Belgium; for research use–
only reagents) on the Luminex 100 immunoassay platform
and IS v.2.3 software (Luminex, Austin, TX, USA) with a
fully automated sample preparation approach [25,26].
MRI scan processing was performed with the Freesurfer
image analysis software suite as explained above.
Statistical analysis
All the statistical procedures were carried out using R
software [27]. Because of the shape of the empirical
amyloid data distributions, the amyloid fractions were
assumed following a lognormal distribution. Logarithms
of Aβ concentrations were used in calculations. Because
logarithms must be used only for dimensionless quantities,
the Aβ fractions were transformed into dimensionless num-
bers by dividing them by a constant. Thus, for any fraction,
a new quantity Aβln was calculated as Aβln ¼ ln AβiAβh i
 
,
where i runs over individuals and 〈Aβ〉 is the median value
for the fraction. This new quantity characterized the amyl-
oid fraction distributions in plasma for the present study.
Pearson partial correlations were calculated between
the MRI measurements for 45 ROIs given in the Freesurfer
subcortical atlas and different Aβln values with age, gender
and ApoE, education and creatinine levels [28-30] as co-
variates. The same procedure was applied to ADNI data.
Partial correlations were calculated with ApoE, age, gen-
der and education and creatinine levels as covariates.
Pearson partial correlations adjusted for the covariates
age, gender and ApoE, education and creatinine levels
were also calculated between Aβln values and cortical vol-
umes and cortical thickness average for 68 ROIs in the
Freesurfer cortical atlas. There was no correction for mul-
tiple comparisons in any case.
The whole procedure was repeated for both data sets,
AB128 and ADNI, taking age, gender and ApoE, educa-
tion and creatinine levels and phenotype as covariates.
Partial correlations were calculated between the 45 Free-
surfer subcortical atlas ROI volumes and Aβln values
and also between the 68 Freesurfer cortical atlas ROI
volumes and thickness average values and Aβln values.
No correction for multiple comparisons was done.
An additional analysis was performed to determine the
association between Aβln CP Aβ(1–40) values and more
correlated brain ROIs was conducted. The subjects were
divided into phenotype groups (AD, MCI and HC), and
each group was analyzed separately. Linear regressions
were performed between Aβln CP Aβ(1–40) and left hip-
pocampal volume in each case.
Finally, Pearson partial correlations adjusted for the
covariates age, gender and ApoE, education and creatininelevels were also calculated between Aβln values for each
amyloid fraction and MMSE score.
Results
Partial Pearson correlations were calculated for 45 ROIs
contained in the Freesurfer subcortical atlas, and Aβln
compartments with age, gender and ApoE, education and
creatinine levels were taken as covariates (see Additional
file 1: Table S1a). The left hippocampal volume was
the top brain ROI for Aβln CP Aβ(1–40) fraction
(pcor = −0.37, P =0.0007), as shown in Table 3. Fur-
thermore, the only Aβln fraction that remained signifi-
cant when associated with left hippocampal volume
was again the Aβln CP Aβ(1–40) fraction.
The same procedure was repeated between the plasma
Aβln values and 68 ROI volumes from the Freesurfer
cortical atlas and thickness average segmented in Freesurfer
(Additional file 1: Tables S1b and S1c). Here the left hemi-
sphere entorhinal volume (pcor = −0.3, P = 0.008) and
left hemisphere entorhinal thickness average (pcor = −0.2,
P = 0.06) emerged as the most significant cortical mea-
surements for Aβln CP Aβ(1–40).
Pearson correlations were repeated, but this time also
including phenotype as a covariate (see Additional file 2:
Table S2). Again, the left hippocampus was the top brain
ROI for Aβln CP Aβ(1–40) fraction (pcor = −0.35, P =0.002)
for subcortical volumes, as shown in Table 3. Left hemi-
sphere entorhinal volume (pcor = −0.3, P =0.008) was the
most significant of the cortical volumes (pcor = −0.27,
P =0.02) and thickness average (pcor = −0.2, P =0.1) for
Aβln CP Aβ(1–40).
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lated to cell-bound Aβ fractions, which are not measured
in the conventional assays available. A similar analysis
using the ADNI data set was performed, although Aβ
levels measured in that series were restricted to a single
plasma measurement (equivalent to TP fraction in our
assay) adjusted for the covariates age, gender, ApoE, edu-
cation and creatinine levels, and no association was found.
In addition, no association was obtained when the analysis
was adjusted for the covariates age, gender, ApoE, educa-
tion, creatinine levels and diagnostic category. These re-
sults are fully compatible with our findings in TP. The
partial correlations between Aβln values and left hippo-
campal volume adjusted for the covariates age, gender and
ApoE, education and creatinine levels are shown in
Table 3. The partial correlations when phenotype was
added as a covariate are also shown in Table 3.
Stratification analyses by phenotypic groups suggested
that each diagnostic group had a similar correlation with
left hippocampal volume in terms of effect size and sig-
nificance. In other words, the observed correlations can-
not be attributed to any specific cognitive subgroup, as
shown in Figure 1. Pearson partial correlation analysis of
Aβln values and MMSE scores showed no correlation be-
tween both magnitudes.
Discussion
The major finding of this study is that cell-bound Aβ
was correlated with left hippocampal volume, a major
area of AD pathology. Therefore, even when cell-bound
Aβ levels do not distinguish HC, MCI and AD satisfactor-
ily [4], they are related to their physiological counterpart,
hippocampal damage. Diluted and undiluted plasma Aβ
levels did not significantly correlate with hippocampal vol-






















Figure 1 Hippocampal volume versus amyloid regression.
Graph shows results of linear regression analysis of the left
hippocampal volume and amyloid-β (Aβ) levels of Aβln cellular pellet
(CP) Aβ(1–40) in the healthy control (HC), minor cognitive impairment
(MCI) and Alzheimer’s disease (AD) groups.in blood have included analysis of only plasma levels, and
the most important Aβ carriers in the blood, which are
the cell membranes, have been systematically ignored
[12]. We used Aβ plasma and MRI measurements taken
from the ADNI project and observed a relationship simi-
lar to the one in our data. The plasma Aβ fractions have
proven to be unrelated to any specific brain region in the
ADNI or AB128 data sets. This fact points to a different
behavior, biochemically, for the Aβ(1–40) and Aβ(1–42)
biomarkers measured with the traditional kit as well as
the CP Aβ(1–40) fraction measured in this study.
On the other hand, the relationship we found seems to
be independent of subject phenotype. Indeed, the simi-
larity between the correlations with and without pheno-
type as covariates points out that the relationship to
hippocampal volume is purely physiological. The same
conclusion can be extrapolated from the slopes of linear
regressions between left hippocampal volume and Aβln
CP Aβ(1–40) level shown in Figure 1. Notice that the
slopes represent approximately the same value for each
group. Additional confirmation is provided by the fact
that no correlation was found between MMSE score
and Aβln CP Aβ(1–40) level.
The unexpected association between CP Aβ(1–40) level
and left hippocampal volume was examined exhaustively
and, after a statistical analysis, proved to be consistent
enough to be reported. This newly established relationship
deserves further research. Even when replications were
needed, the ad hoc analysis showed that blood CP
Aβ(1–40) level could be used as a suggestive proxy for
hippocampal volume and thus could be a useful screen
for AD, even if it must be used with other biomarkers.
Further studies are necessary to validate this working
hypothesis.
The major limitation of this study is the sample size.
The study in fact involved a modest number of subjects.
Only independent replications will be able to help clarify
whether the observed associations and statistical signifi-
cance are related to true findings or to random statistical
oscillations. If we can finally confirm this observation,
our findings may open new avenues to developing an
AD biomarker related to the intrinsic properties of Aβ
bound to blood cells. This finding might also have sev-
eral physiological and pathological implications beyond
the scope of this study. Another important limitation of
the study is that no correction for multiple comparisons
was done. Therefore, further studies are necessary to
clarify the effect and function of Aβ peptides bound to
different blood cells.
Conclusions
The cell-bound Aβ(1–40) fraction was found to correlate
with volume in the left hippocampus, a major site of AD
pathology. However, other plasma Aβ fractions did not
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ferent behavior, biochemically, for the traditionally mea-
sured Aβ(1–40) and Aβ(1–42) biomarkers and the CP
Aβ(1–40) fraction. This newly established relationship
deserves further research. Blood CP Aβ(1–40) may prove
to be a useful screening test for AD, even as part of a
composite biomarker.
Additional files
Additional file 1: Table S1. Excel spreadsheet with partial correlations
adjusted for the covariates age, ApoE, gender, education and creatinine
levels. (a) Partial Pearson correlations between amyloid-β fractions and
volume Freesurfer subcortical ROIs. (b) Partial Pearson correlations
between amyloid-β fractions and volume of Freesurfer cortical ROIs. (c)
Partial Pearson correlations between amyloid-β fractions and cortical
thickness of Freesurfer cortical ROIs.
Additional file 2: Table S2. Excel spreadsheet with partial correlations
adjusted for the covariates age, ApoE, gender, education, creatinine levels
and phenotype. (a) Partial Pearson correlations between amyloid-β fractions
and volume Freesurfer subcortical ROIs. (b) Partial Pearson correlations
between amyloid-β fractions and volume of Freesurfer cortical ROIs. (c) Partial
Pearson correlations between amyloid-β fractions and cortical thickness of
Freesurfer cortical ROIs.
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